The global market for Neuroendocrine Tumors Therapeutics was valued at US$3.8 Billion in 2024 and is projected to reach US$6.6 Billion by 2030, growing at a CAGR of 9.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
As research into NETs advances, new therapeutic options such as peptide receptor radionuclide therapy (PRRT) and novel somatostatin analogs have emerged, offering hope for improved management of this rare condition. The development of these therapies is complemented by innovations in diagnostic imaging, such as Gallium-68 DOTATATE PET scans, which provide precise localization of neuroendocrine tumors. These technological advancements not only enhance the accuracy of diagnosis but also allow for the effective monitoring of treatment response, thereby optimizing patient management strategies.
The growth in the neuroendocrine tumors therapeutics market is driven by several factors, including increased awareness of NETs, advancements in diagnostic methods, and the introduction of innovative treatments that target specific molecular pathways involved in tumor growth. Additionally, the rising prevalence of NETs and the aging global population contribute to the expanding demand for effective treatments. Pharmaceutical companies continue to invest in the development of more efficacious and less toxic therapeutic options, while regulatory agencies support these initiatives through accelerated approval processes for drugs that address unmet medical needs in the NET patient community.
Key Trends and Drivers
Neuroendocrine tumors (NETs) represent a complex group of cancers arising from neuroendocrine cells throughout the body, requiring multifaceted treatment approaches. These tumors vary widely in their behavior, often being slow-growing and asymptomatic, which complicates early diagnosis and treatment. The management of NETs typically involves a combination of surgery, hormonal therapy, chemotherapy, and targeted biological therapies, each tailored to the tumor type, location, and genetic profile. Recent years have seen significant advancements in the understanding of NET biology, driving the development of new targeted therapies and improving diagnostic techniques.As research into NETs advances, new therapeutic options such as peptide receptor radionuclide therapy (PRRT) and novel somatostatin analogs have emerged, offering hope for improved management of this rare condition. The development of these therapies is complemented by innovations in diagnostic imaging, such as Gallium-68 DOTATATE PET scans, which provide precise localization of neuroendocrine tumors. These technological advancements not only enhance the accuracy of diagnosis but also allow for the effective monitoring of treatment response, thereby optimizing patient management strategies.
The growth in the neuroendocrine tumors therapeutics market is driven by several factors, including increased awareness of NETs, advancements in diagnostic methods, and the introduction of innovative treatments that target specific molecular pathways involved in tumor growth. Additionally, the rising prevalence of NETs and the aging global population contribute to the expanding demand for effective treatments. Pharmaceutical companies continue to invest in the development of more efficacious and less toxic therapeutic options, while regulatory agencies support these initiatives through accelerated approval processes for drugs that address unmet medical needs in the NET patient community.
Report Scope
The report analyzes the Neuroendocrine Tumors Therapeutics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Product Segment (Somatostatin Analogs, Targeted Therapy, Other Product Segments); End-Use (Hospital End-Use, Clinics End-Use, Other End-Uses).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Somatostatin Analogs segment, which is expected to reach US$3.8 Billion by 2030 with a CAGR of a 8.5%. The Targeted Therapy segment is also set to grow at 11.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $1 Billion in 2024, and China, forecasted to grow at an impressive 8% CAGR to reach $970.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Eli Lilly and Company and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Neuroendocrine Tumors Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neuroendocrine Tumors Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Neuroendocrine Tumors Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 36 major companies featured in this Neuroendocrine Tumors Therapeutics market report include:
- AbbVie, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Co., Ltd.
- Eli Lilly and Company
- Exelixis, Inc.
- HUTCHMED
- Ipsen Pharma
- Isotopen Technologien MA¼nchen
- Lantheus Holdings, Inc.
- Merck & Co., Inc.
- Neurocrine Biosciences, Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Co., Ltd.
- Eli Lilly and Company
- Exelixis, Inc.
- HUTCHMED
- Ipsen Pharma
- Isotopen Technologien MA¼nchen
- Lantheus Holdings, Inc.
- Merck & Co., Inc.
- Neurocrine Biosciences, Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 171 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.8 Billion |
| Forecasted Market Value ( USD | $ 6.6 Billion |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | Global |
